

Nanologica AB (publ) Receives Additional Order of approx. SEK 2.7 Million from Customer in the US

Nanologica has received a supplementary order for the company's silica-based purification media NLAB Saga® from a customer in the US who placed an initial order of approximately SEK 1.3 million in June. The customer is a manufacturer of peptide drugs and the order relates to evaluation of NLAB Saga® on a production scale.

In June, Nanologica received a first order from this customer in the US for evaluation of the company's silica on a production scale. The customer's evaluation is based on NLAB Saga® from different batches, which is why the initial order is now being completed. The order value is USD 283,400, which corresponds to approximately SEK 2.7 million at today's exchange rate.

"The customer wants to evaluate NLAB Saga® from different batches, which is a clear indication that it is an evaluation with the aim of including our product in their production. The fact that our production is now stable and that we can thus deliver according to the customer's wishes is pivotal for us to now be able to acknowledge this order," Nanologica's CEO Andreas Bhagwani comments.

The order is expected to be delivered in the fourth quarter.

For further information, please contact

Johanna Johansson
Director IR, Communications and Marketing
johanna.johansson@nanologica.com
+46 72 211 21 90

About Nanologica AB (publ)

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica's products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.

This information is information that Nanologica AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-10-16 16:34 CEST.

Attachments

[Nanologica AB \(publ\) Receives Additional Order of approx. SEK 2.7 Million from Customer in the US](#)